Literature DB >> 15297131

Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer.

Barbara Bussels1, Annelies Maes, Robert Hermans, Sandra Nuyts, Caroline Weltens, Walter Van den Bogaert.   

Abstract

BACKGROUND AND
PURPOSE: Evaluation of loco-regional failure patterns and survival after parotid-sparing three-dimensional conformal and intensity modulated radiotherapy (IMRT) for head and neck cancer. PATIENTS AND METHODS: From June 1999 to July 2002, seventy-two patients with lateralised head and neck tumours, excluding nasopharyngeal tumours and patients with bilateral or contralateral neck disease, were irradiated with a parotid-sparing technique. Three-dimensional conformal planning was used in 68 patients, 4 patients were treated with dynamic IMRT. Bilateral neck node irradiation was performed in all patients, the junctional (or high level II) nodes, contralateral to the tumour, however, were excluded from the clinical target volume to spare the adjacent parotid from irradiation. In 20 patients with persistent or recurrent loco-regional disease, the localisation and volume of the treatment failure, as determined by computed tomography (CT), was copied on the pre-treatment CT-study used for treatment planning. Minimum, mean and maximum doses administered to the region of the failure were calculated and dose--volume histograms were computed of each failure. The failures were divided in three groups depending on the percentage of their volume receiving 95% of the prescribed dose. Recurrences were defined to be in-field (IF) if >95% of their volume received 95% of the prescribed dose and out-field (OF) if <20% of their volume received 95% of the prescribed dose. When 20-95% of the volume of the recurrence received 95% of the prescribed dose, this recurrence was defined as extending outside the field (EOF).
RESULTS: With a median follow-up time of 19 months, the 2-year loco-regional control rate was 69% with primary radiotherapy and 63.5% with surgery followed by irradiation (P = 0.77). The 2-year overall survival rate for the entire patient population was 67.4%. At the time of analysis, 20 of the 72 patients had developed a loco-regional failure; 2 patients (2/20) presented with a loco-regional relapse combined with distant metastasis. Fifteen of the 20 loco-regional failures (15/20) occurred within the high dose region (IF). Five patients (5/20) developed a failure of which the bulky tumour mass was located within the high dose region but extending outside the treatment volume (EOF). No relapses were seen out-field (OF) and no patients relapsed in the spared junctional area contralateral to the tumour.
CONCLUSIONS: The selection of patients treated with parotid-sparing radiotherapy, by omitting irradiation to the junctional nodes contralateral to the tumour, proved to be safe in our hands, since no recurrences developed in the spared area. As this parotid-sparing technique reduces significantly the dose to the contralateral parotid and is easy to perform, it should be considered for all selected patients.

Entities:  

Mesh:

Year:  2004        PMID: 15297131     DOI: 10.1016/j.radonc.2004.03.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  13 in total

Review 1.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

2.  Outcome after re-irradiation of head and neck cancer patients.

Authors:  Nele Platteaux; Piet Dirix; Bianca Vanstraelen; Sandra Nuyts
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

3.  Clinical outcomes for larynx patients with cancer treated with refinement of high-dose radiation treatment volumes.

Authors:  Adam R Burr; Paul M Harari; Alyx M Haasl; Aaron M Wieland; Justine Y Bruce; Randall J Kimple; Gregory K Hartig; Timothy M McCulloch; Matthew E Witek
Journal:  Head Neck       Date:  2020-02-14       Impact factor: 3.147

4.  Pattern of failure after helical tomotherapy in head and neck cancer.

Authors:  Ashraf Farrag; Mia Voordeckers; Koen Tournel; Peter De Coninck; Guy Storme
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

5.  Applications of diffusion-weighted magnetic resonance imaging in head and neck squamous cell carcinoma.

Authors:  Vincent Vandecaveye; Frederik De Keyzer; Piet Dirix; Maarten Lambrecht; Sandra Nuyts; Robert Hermans
Journal:  Neuroradiology       Date:  2010-07-15       Impact factor: 2.804

Review 6.  Dysphagia in head and neck cancer patients treated with chemoradiotherapy.

Authors:  Nele Platteaux; Piet Dirix; Eddy Dejaeger; Sandra Nuyts
Journal:  Dysphagia       Date:  2009-08-27       Impact factor: 3.438

7.  Incorporating PET information in radiation therapy planning.

Authors:  M Macmanus; T Leong
Journal:  Biomed Imaging Interv J       Date:  2007-01-01

8.  Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control.

Authors:  Enrique Chajon; Caroline Lafond; Guillaume Louvel; Joël Castelli; Danièle Williaume; Olivier Henry; Franck Jégoux; Elodie Vauléon; Jean-Pierre Manens; Elisabeth Le Prisé; Renaud de Crevoisier
Journal:  Radiat Oncol       Date:  2013-05-30       Impact factor: 3.481

9.  Feasibility of image-guided radiotherapy based on helical tomotherapy to reduce contralateral parotid dose in head and neck cancer.

Authors:  Nam P Nguyen; Paul Vos; Vincent Vinh-Hung; Misty Ceizyk; Lexie Smith-Raymond; Michelle Stevie; Benjamin Slane; Alexander Chi; Anand Desai; Shane P Krafft; Siyoung Jang; Russ Hamilton; Ulf Karlsson; Dave Abraham
Journal:  BMC Cancer       Date:  2012-05-11       Impact factor: 4.430

Review 10.  Diffusion-weighted magnetic resonance imaging in neck lymph adenopathy.

Authors:  Vincent Vandecaveye; Frederik De Keyzer; Robert Hermans
Journal:  Cancer Imaging       Date:  2008-09-30       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.